News Releases

Date Title and Summary Additional Formats
Sep 11, 2019
LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 To Accrue Contingent Interest
BURLINGTON, N.C. --(BUSINESS WIRE)--Sep. 11, 2019-- LabCorp® (NYSE: LH) announced today that for the period of Sept. 11, 2019 to March 10, 2020 , its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will, subject to the terms of the Zero Coupon Notes, accrue contingent cash
Sep 10, 2019
Covance Unveils New R&D Center in Shanghai
Inauguration Ceremony Highlights World-Class, Comprehensive Drug Development Capabilities and More Than Two Decades of Growth in China BURLINGTON, N.C. --(BUSINESS WIRE)--Sep. 10, 2019-- LabCorp® (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care,
Aug 29, 2019
LabCorp is Scheduled to Present at the Morgan Stanley Global Healthcare Conference
BURLINGTON, N.C. --(BUSINESS WIRE)--Aug. 29, 2019-- LabCorp® (NYSE: LH) today announced it will participate at the Morgan Stanley Global Healthcare Conference . LabCorp’s presentation is planned for Monday, Sept. 9, 2019 at 9:55 a.m. ET . A live audio webcast will be available via the Company
Aug 29, 2019
Covance Launches Laboratory Data Management Functional Service Provider for Pharmaceutical and Biotechnology Customers
Program Expands the Company’s Growing and Unique FSPx Capabilities BURLINGTON, N.C. --(BUSINESS WIRE)--Aug. 29, 2019-- LabCorp® (NYSE: LH), a leading global life sciences company, today announced that its Covance Drug Development business has launched a laboratory solution within its functional
Jul 25, 2019
LabCorp Announces 2019 Second Quarter Results and Updates 2019 Guidance
Q2 revenue of $2.88 billion , up 0.5% from $2.87 billion last year; excluding the disposition of businesses revenue grew 2.4% Q2 diluted EPS of $1.93 , down 15% from $2.27 last year; Q2 adjusted EPS of $2.93 , down 2% from $2.98 last year 2019 adjusted EPS guidance of $11.10 to $11.40 , up 1% to 3%
Jul 22, 2019
LabCorp Expands Consumer-Initiated Test Offering
Pixel by LabCorp Now Available with Phlebotomy Collection Through LabCorp’s Nationwide Patient Service Center Network BURLINGTON, N.C. --(BUSINESS WIRE)--Jul. 22, 2019-- LabCorp® (NYSE: LH), a leading global life sciences company, today announced a significant expansion to its Pixel by LabCorp™
Jul 01, 2019
Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021
BURLINGTON, N.C. --(BUSINESS WIRE)--Jul. 1, 2019-- LabCorp® (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below. The Zero Coupon Notes are convertible into cash and Common Stock of LabCorp, if any, subject
Jun 25, 2019
LabCorp to Announce Second Quarter Financial Results on July 25, 2019
BURLINGTON, N.C. --(BUSINESS WIRE)--Jun. 25, 2019-- LabCorp® (NYSE: LH) will release its second quarter of 2019 financial results before the market opens on Thursday, July 25, 2019 , followed by a conference call and webcast beginning at 9:00 a.m. EDT to discuss the results.
Jun 18, 2019
LabCorp and Mount Sinai Health System Collaborate to Establish Digital and AI-Enabled Pathology Center of Excellence
Philips IntelliSite Pathology Solution will be deployed across the Mount Sinai Health System to support greater efficiency and help improve patient care BURLINGTON, N.C. & NEW YORK & AMSTERDAM--(BUSINESS WIRE)--Jun. 18, 2019-- LabCorp® (NYSE: LH) and the Mount Sinai Health System today announced
Jun 07, 2019
Jun 05, 2019
LabCorp Announces New Leadership Roles
David P. King , current chairman, president and CEO of LabCorp, to become executive chairman of the board of directors effective Nov. 1 , retiring Oct. 31 as president and CEO Adam H. Schechter , current lead independent director of LabCorp and longtime Merck executive, to become president and CEO
Jun 03, 2019
LabCorp Announces New Term Loan Facility
BURLINGTON, N.C. --(BUSINESS WIRE)--Jun. 3, 2019-- On June 3, 2019 , LabCorp® (NYSE: LH) entered into a new Term Loan Credit Agreement, which provides for a two-year term loan credit facility in the principal amount of $850 million (the “New Term Loan Facility”). Bank of America, N.A.
Jun 03, 2019
LabCorp and Envigo Complete Innovative Transactions
LabCorp Acquires Envigo’s Global Nonclinical Contract Research Business, Envigo Acquires LabCorp’s Covance Research Products Business BURLINGTON, N.C. & INDIANAPOLIS --(BUSINESS WIRE)--Jun. 3, 2019-- LabCorp® (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding
May 10, 2019
LabCorp Announces Availability of New QIAGEN therascreen FGFR mutation analysis companion diagnostic for Bladder Cancer
New Test Further Underscores LabCorp’s Leadership in Development and Commercialization of Innovative Lab Testing BURLINGTON, N.C. --(BUSINESS WIRE)--May 10, 2019-- LabCorp® (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced the
May 02, 2019
LabCorp to Webcast Its Annual Meeting of Shareholders
BURLINGTON, N.C. --(BUSINESS WIRE)--May 2, 2019-- LabCorp® (NYSE: LH) today announced that its Annual Meeting of Shareholders will be webcast live beginning May 9, 2019 , at 9:00 a.m. Eastern Daylight Time via the Company website at www.LabCorp.com . An archived replay of the audio webcast will be
Apr 30, 2019
LabCorp Announces 2019 First Quarter Results and Increases 2019 Earnings Guidance
Q1 revenue of $2.79 billion , down 2% from $2.85 billion last year Q1 diluted EPS of $1.86 , up 11% from $1.67 last year; Q1 adjusted EPS of $2.62 , down 6% from $2.78 last year 2019 adjusted EPS guidance increased to $11.05 to $11.45 , from $11.00 to $11.40 2019 free cash flow guidance of $950
Apr 17, 2019
LabCorp and Envigo Sign Innovative Agreement to Expand Covance’s Nonclinical Drug Development Capabilities and Create an Independent Research Models Provider
LabCorp will purchase Envigo’s nonclinical contract research services business, expanding the global reach and capabilities of Covance’s nonclinical drug development business Envigo’s research models and services business will purchase Covance’s research products business located in the United
Apr 01, 2019
LabCorp to Announce First Quarter Financial Results on April 30, 2019
BURLINGTON, N.C. --(BUSINESS WIRE)--Apr. 1, 2019-- LabCorp® (NYSE: LH) will release its first quarter of 2019 financial results before the market opens on Tuesday, April 30, 2019 , followed by a conference call and webcast beginning at 9:00 a.m. EDT to discuss the results.
Apr 01, 2019
Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021
BURLINGTON, N.C. --(BUSINESS WIRE)--Apr. 1, 2019-- LabCorp® (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below. The Zero Coupon Notes are convertible into cash and Common Stock of LabCorp, if any, subject
Mar 28, 2019
LabCorp Earns 100 Percent on Human Rights Campaign Foundation’s 17th Annual Scorecard on LGBTQ Workplace Equality
Receives Designation as a Best Place to Work for LGBTQ Equality for Second Year in a Row BURLINGTON, N.C. --(BUSINESS WIRE)--Mar. 28, 2019-- LabCorp® (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced that it received a perfect
Mar 11, 2019
LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest
BURLINGTON, N.C. --(BUSINESS WIRE)--Mar. 11, 2019-- LabCorp® (NYSE: LH) announced today that for the period of March 11, 2019 to Sept. 10, 2019 , its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will accrue (subject to the terms of the Zero Coupon Notes) contingent cash
Mar 05, 2019
LabCorp is Scheduled to Present at the 2019 Barclays Global Healthcare Conference
BURLINGTON, N.C. --(BUSINESS WIRE)--Mar. 5, 2019-- LabCorp® (NYSE: LH) today announced it will participate at the 2019 Barclays Global Healthcare Conference . LabCorp’s presentation is planned for Tuesday, March 12, 2019 , at 8:30 a.m. (ET) . A live audio webcast of the presentation will be
Feb 19, 2019
Feb 07, 2019
LabCorp Announces 2018 Fourth Quarter and Full Year Results and Provides 2019 Guidance
Revenue: Q4 of $2.8 billion , up 2% over 2017; Full year of $11.3 billion , up 10% over 2017 Diluted EPS: Q4 of $1.56 ; Full year of $8.61 Adjusted EPS: Q4 of $2.52 , up 11% over 2017; Full year of $11.02 , up 20% over 2017 2019 Adjusted EPS guidance of $11.00 to $11.40 2019 Free Cash Flow guidance
Jan 22, 2019
LabCorp Named to FORTUNE Magazine's 2019 List of ‘World’s Most Admired Companies,’ Making the Annual List for the Second Consecutive Year
BURLINGTON, N.C. --(BUSINESS WIRE)--Jan. 22, 2019-- LabCorp® (NYSE: LH), a leading global life sciences company, today announced that it has been named to  FORTUNE  magazine's 2019 List of World’s Most Admired Companies, making the annual list for the second consecutive year.